UroGen Pharma (NASDAQ:URGN) received United States FDA clearance for its Investigational New Drug application to initiate clinical evaluations of its next-generation oncolytic virus treatment UGN-501.
Azenta (NASDAQ:AZTA) completed the sale of its B Medical Systems business to Thelema S.à r.l. on July 1, 2026.
Chemomab Therapeutics (NASDAQ:CMMB) and Scipher Medicine announced a stock-based merger agreement that will create Scipher Medicine Corporation, which is expected to trade under the ticker symbol “SCIP.”
BTQ Technologies (NASDAQ:BTQ) completed the acquisition of QPerfect, a France-based quantum software company, strengthening its Quantum Ready infrastructure platform.
Johnson & Johnson (NYSE:JNJ) secured United States FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform to treat increasingly complex cardiac cases using a single integrated catheter.
The United States Food and Drug Administration accepted a New Drug Application from Immunome (NASDAQ:IMNM) for its oral tumor treatment varegacestat following clinical trial data showing an 84% reduction in disease progression risk.
Odysight.ai (NASDAQ:ODYS) received a purchase order valued at approximately $0.3 million (NIS 1.0 million) from Elbit Systems to supply its specialized health monitoring software.
Sono-Tek (NASDAQ:SOTK) reported fiscal first-quarter 2027 results for the period ended May 31, 2026, with net sales increasing 10% to $5.66 million, mainly driven by demand from medical markets.
Diana Shipping (NYSE:DSX), the largest shareholder of Genco Shipping & Trading (NYSE:GNK), urged Genco investors to tender shares by July 10, 2026, at 5:00 p.m. Eastern Time under its acquisition proposal.
OR Royalties (NYSE:OR) generated 20,757 gold equivalent ounces in preliminary second-quarter asset deliveries to drive strong cyclical performance gains across its streaming portfolio.
AerCap Holdings (NYSE:AER) signed lease agreements with China Southern Group for three Boeing 777-300ERSF converted freighter aircraft to support the airline’s cargo operations.
BioLineRx (NASDAQ:BLRX) and Hemispherian reported positive preclinical data from a patient-derived ovarian cancer xenograft model showing a strong therapeutic synergy between its small-molecule candidate GLIX1 and the approved PARP inhibitor olaparib.
